Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

(2014) Aaron Scott Mansfield et al.   Journal of Thoracic Oncology

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

(2013) Vamsidhar Velcheti et al.   Journal of Thoracic Oncology

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

(2013) Luana Calabrò et al.   LANCET ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations

(2011) Ottavio Rena et al.   JOURNAL OF SURGICAL ONCOLOGY

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

(2010) Lee M. Krug et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

(2010) Noriyuki Yamada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

(2010) R. Hassan et al.   CLINICAL CANCER RESEARCH

Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo

(2009) Koichi Inami et al.   CANCER SCIENCE

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

(2009) R. Karim et al.   CLINICAL CANCER RESEARCH

Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells

(2009) C. Jackaman et al.   EUROPEAN RESPIRATORY JOURNAL

Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma

(2009) Marc de Perrot et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation

(2009) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

PTEN expression is a strong predictor of survival in mesothelioma patients☆

(2008) Isabelle Opitz et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma

(2008) Masaki Anraku et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma

(2008) Siyamek Neragi-Miandoab et al.   International Journal of Surgery